Accepted for/Published in: JMIR Infodemiology
Date Submitted: Oct 6, 2025
Open Peer Review Period: Oct 27, 2025 - Dec 22, 2025
Date Accepted: May 6, 2026
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Mpox on Instagram: A content analytic study
ABSTRACT
Background:
Mpox was declared a public health emergency of international concern in 2022. Instagram is widely used by age groups and communities disproportionately affected by mpox, yet platform-specific evidence on mpox information characteristics and engagement is limited.
Objective:
To characterize sources, content, and engagement features of mpox-related Instagram posts, to describe prevention and treatment framing, and to compare the top 10% most-liked posts with the remaining corpus.
Methods:
We retrieved English-language public Instagram posts via CrowdTangle containing “mpox” or “monkeypox” dated May 5, 2022 to January 17, 2023 (initial N=18,616). Using a pretested, deductive codebook adapted from prior Instagram health studies, two coders completed two pilot rounds; variables with low agreement were excluded. Interrater reliability across retained variables showed mean κ=0.70 (median κ=0.83). A randomized analytic sample of N=1,000 posts was coded for source type, content features, and prevention/treatment framing. Descriptive statistics were computed. For engagement contrasts, we compared the top 10% most-liked posts with the bottom 90% using tests of differences in independent proportions (mean differences [MD] with p-values).
Results:
Most posts originated from organizations (76.0%) versus individuals (24.0%). Organizational sources most commonly included businesses (57.4%) and news/media outlets (52.8%); government (22.9%), nonprofits (17.3%), and health-care organizations (9.2%) were less frequent. About one-third of posts cited a source (34.4%), most often the WHO and CDC/other federal entity. Posts predominantly used illustrated images/infographics (82.7%); photos appeared in 47.3% and videos in 12.4% of posts. Prevention content appeared in 38.4% of posts, most commonly vaccination (68.5% of prevention posts), followed by avoiding close contact (14.5%), avoiding contact with objects (8.3%), abstaining from sexual activity (7.6%), and condom use (1.3%); 28.9% of prevention posts noted barriers. Treatment mentions were uncommon (2.5% traditional biomedical; 0.2% alternative). Compared with the bottom 90%, the top 10% most-liked posts: 1) were more likely to originate from public figures/celebrities among individuals (MD=-0.591; p<.001) and from businesses (MD=-0.299; p<.001) or news/media (MD=-0.350; p<.001) among organizations; 2) were less likely to be from government, nonprofit, or health-care organizations (all p<.01); and more often included non-moving images (MD=-0.119; p<.05), visible lesion depictions (MD=-0.081; p<.05), prevalence mentions (MD=-0.180; p<.001), and citations (MD=-0.162; p<.01).
Conclusions:
During the initial outbreak period, highly engaged mpox content on Instagram skewed toward posts by public figures and news/business accounts and toward static, citation-bearing visuals that included prevalence context and occasionally lesion imagery. Public-health communicators seeking reach on Instagram should prioritize clear static infographics with explicit source citation and epidemiologic context and consider co-publishing with trusted creators and news outlets, while addressing access barriers highlighted in prevention posts.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.